Podcast
Questions and Answers
Enzyme replacement therapy (ERT) involves the administration of recombinant human glucocerebrosidase to replace the missing or defective enzyme responsible for the accumulation of glucosylceramide.
Enzyme replacement therapy (ERT) involves the administration of recombinant human glucocerebrosidase to replace the missing or defective enzyme responsible for the accumulation of glucosylceramide.
True
Substrate reduction therapy (SRT) targets the breakdown process of glucosylceramide rather than its rate of synthesis.
Substrate reduction therapy (SRT) targets the breakdown process of glucosylceramide rather than its rate of synthesis.
False
Gaucher disease is a lysosomal storage disorder characterized by a deficiency in the enzyme glucocerebrosidase, leading to the accumulation of $\alpha$-galactosylceramide.
Gaucher disease is a lysosomal storage disorder characterized by a deficiency in the enzyme glucocerebrosidase, leading to the accumulation of $\alpha$-galactosylceramide.
False
Enzyme replacement therapy (ERT) with velaglucerase (Cerezyme®) and taliglucerase alfa (Elelyso®) is the only approved treatment for Gaucher disease.
Enzyme replacement therapy (ERT) with velaglucerase (Cerezyme®) and taliglucerase alfa (Elelyso®) is the only approved treatment for Gaucher disease.
Signup and view all the answers
Diagnosis of Gaucher disease typically involves detecting reduced activity of the enzyme glucocerebrosidase in leukocytes and identifying mutations in the GBA2 gene.
Diagnosis of Gaucher disease typically involves detecting reduced activity of the enzyme glucocerebrosidase in leukocytes and identifying mutations in the GBA2 gene.
Signup and view all the answers
Study Notes
Introduction
Gaucher disease (GD), also known as glucocerebrosidase deficiency or Gaucher's disease, is a rare, autosomal recessive lysosomal storage disorder that results from a deficiency of the lysosomal enzyme glucocerebrosidase (GCase). This deficiency leads to the progressive accumulation of the substrate, glucosylceramide, within macrophages, particularly those in the reticuloendothelial system, contributing to the characteristic clinical features seen in this condition.
Pathophysiology
Under normal circumstances, glucocerebrosidase breaks down glucosylceramide into ceramide and glucose, thereby preventing its harmful accumulation inside cells. However, when there is a deficiency in glucocerebrosidase production or function, the excess glucosylceramide cannot be broken down effectively. As a consequence, it accumulates within macrophages, resulting in their engulfment, leading to a chronic inflammation response and consequent tissue damage.
Diagnosis
Diagnosis of GD involves detecting reduced acid glucocerebrosidase activity in leukocytes, typically white blood cells, and identification of mutations in the GBA1 gene, which encodes the enzyme. Newborn screening programs have been implemented in several countries to identify GD in its earliest stages, allowing timely intervention to prevent complications related to the disease.
Treatment Options
Two primary treatment approaches exist for GD: enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
Enzyme Replacement Therapy (ERT)
Enzyme replacement therapy involves the administration of recombinant human glucocerebrosidase via intravenous infusion to replace the missing or defective enzyme responsible for the accumulation of glucosylceramide. ERT has been shown to reduce the levels of glucosylceramide and ameliorate many of the signs and symptoms associated with GD. Currently, two forms of ERT are approved for use: velaglucerase (Cerezyme®) and taliglucerase alfa (Elelyso®).
Substrate Reduction Therapy (SRT)
Substrate reduction therapy targets the rate of synthesis of glucosylceramide rather than the breakdown process. It utilizes oral medications called miglustat (Zavesca®) and eliglustat (Cerdelga®) to inhibit the conversion of glucosylceramide synthase to glucosylceramide. By blocking this step, the overall formation of glucosylceramide within the cell is decreased, which can help to alleviate the accumulation of this substrate and reduce disease progression.
Conclusion
Gaucher disease is a rare lysosomal storage disorder characterized by glucocerebrosidase deficiency leading to excessive glucosylceramide accumulation within macrophages. This condition has variable clinical manifestations depending on the type (type 1, type 2, or type 3) and associated neurological involvement. Diagnosis typically involves detecting reduced enzyme activity in leukocytes and identifying mutations in the GBA1 gene. Two primary treatment approaches exist for GD: enzyme replacement therapy using recombinant human glucocerebrosidase and substrate reduction therapy with inhibitors of glucosylceramide synthesis.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz covers the pathophysiology, diagnosis, and treatment options available for Gaucher disease, a rare lysosomal storage disorder caused by glucocerebrosidase deficiency. Learn about how the accumulation of glucosylceramide impacts macrophages, the diagnostic methods involving enzyme activity and genetic mutations, and the two main treatment approaches: enzyme replacement therapy and substrate reduction therapy.
